title: Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
abstract: BACKGROUND
  Accelerated hypofractionated radiotherapy can shorten total treatment time and overcome the accelerated repopulation of tumour cells during radiotherapy. This therapeutic approach has demonstrated good efficacy in the treatment of locally advanced non-small-cell lung cancer (NSCLC). However, the optimal fractionation scheme remains uncertain. The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC.
  
  
  METHODS
  Previously untreated cases of unresectable stage III NSCLC received accelerated hypofractionated 3-DCRT, delivered at 3 Gy per fraction, once daily, with five fractions per week. The starting dose was 66 Gy and an increment of 3 Gy was utilized. Higher doses continued to be tested in patient groups until the emergence of dose-limiting toxicity (DLT). The MTD was regarded as the dose that was one step below the dose at which DLT occurred. Patients received at least one cycle of a concurrent two-drug chemotherapy regimen of NVB and CBP.
  
  
  RESULTS
  A total of 13 patients were enrolled and progressed through three dose escalation groups: 66 Gy, 69 Gy, and 72 Gy. No treatment-related deaths occurred. The major adverse events included radiation oesophagitis, radiation pneumonitis, and neutropenia. Nausea, fatigue, and anorexia were commonly observed, although the magnitude of these events was typically relatively minor. Among the entire group, four instances of DLT were observed, including two cases of grade 3 radiation oesophagitis, one case of grade 3 radiation pneumonitis, and one case of grade 4 neutropenia. All of these cases of DLT occurred in the 72 Gy group. Therefore, 72 Gy was designated as the DLT dose level, and the lower dose of 69 Gy was regarded as the MTD.
  
  
  CONCLUSIONS
  For unresectable stage III NSCLC 69 Gy (at 3 Gy/fraction) was the MTD of accelerated hypofractionated 3-DCRT administered in combination with concurrent NVB and CBP chemotherapy. The toxicity of this chemoradiotherapy regimen could be tolerated. A phase II trial is recommended to further evaluate the efficacy and safety of this regimen.
authors: Department of Oncology, North China Petroleum Bureau General Hospital of Hebei Medical University, 8 Huizhan Avenue, Renqiu, Hebei Province 062552, PR China. zyy_linqiang@hotmail.com
authors: Qiang
authors: Q
authors: Lin
authors: Yue-E
authors: YE
authors: Liu
authors: Xiao-Cang
authors: XC
authors: Ren
authors: Na
authors: N
authors: Wang
authors: Xue-Ji
authors: XJ
authors: Chen
authors: Dong-Ying
authors: DY
authors: Wang
authors: Jie
authors: J
authors: Zong
authors: Yu
authors: Y
authors: Peng
authors: Zhi-Jun
authors: ZJ
authors: Guo
authors: Jing
authors: J
authors: Hu
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy*; D059248:Chemoradiotherapy / Q000379:methods; D015331:Cohort Studies; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D021621:Imaging, Three-Dimensional / Q000379:methods; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011832:Radiation Injuries / Q000209:etiology; D017564:Radiation Pneumonitis / Q000209:etiology; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000379:methods*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D016190:Carboplatin; D000077235:Vinorelbine
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):645-50
references: 20869582
references: JAMA. 2010 Mar 17;303(11):1070-6
references: 20233825
references: Lung Cancer. 2004 Oct;46(1):87-98
references: 15364136
references: Eur J Cancer. 2007 Jan;43(1):114-21
references: 17084621
references: Jpn J Clin Oncol. 2008 Feb;38(2):92-8
references: 18267986
references: Oncologist. 2012;17(5):682-93
references: 22531360
references: J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100
references: 17603311
references: J Clin Oncol. 2004 Jan 1;22(1):45-52
references: 14701767
references: Clin Oncol (R Coll Radiol). 2011 Oct;23(8):561-2
references: 21676603
references: Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):324-33
references: 16168827
references: Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):315-22
references: 8567332
references: Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):23-33
references: 11163494
references: Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1397-404
references: 19117690
references: J Clin Oncol. 1998 Nov;16(11):3518-23
references: 9817269
references: Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):425-34
references: 20980108
references: J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5
references: 8780630
references: Radiother Oncol. 2004 May;71(2):163-6
references: 15110449
references: Oncol Lett. 2011 Jul;2(4):669-674
references: 22848247
references: Eur J Cancer. 2000 Mar;36(5):592-600
references: 10738123
references: J Clin Oncol. 1999 Sep;17(9):2692-9
references: 10561343
references: J Clin Oncol. 2006 Oct 20;24(30):4833-9
references: 17050868
references: Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):385-93
references: 22265460
references: Br J Radiol. 1973 Feb;46(542):151
references: 4686826
references: Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28
references: 15667949
references: Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1106-11
references: 16730134
references: Lancet. 1997 Jul 19;350(9072):161-5
references: 9250182
references: Radiother Oncol. 2011 Mar;98(3):304-8
references: 21345508
references: J Radiat Res. 2013 Jan;54(1):126-34
references: 22988282
references: Acta Med Okayama. 2008 Feb;62(1):37-44
references: 18323870
references: Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):367-72
references: 20457350
references: J Clin Oncol. 2010 May 1;28(13):2181-90
references: 20351327